# SLGL catalysts: Sol-Gel Technologies Ltd. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/slgl/catalysts

> Sol-Gel Technologies Ltd. (SLGL) has no upcoming catalysts in this calendar. The latest recorded is the Sol-Gel Technologies Ltd. topline data readout, Nov 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Sol-Gel Technologies Ltd. |
| Ticker | SLGL (Nasdaq) |
| SEC CIK | 1684693 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/slgl |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 25, 2022 | [Epsolay (epsolay) FDA approval](https://sec-api.dev/pdufa/epsolay) | SLGL |  | completed, approved | "On April 25, 2022, the Company announced that the FDA approved the drug product, Epsolay®, which entitled the Company to a $3.5 million milestone payment, as per the license agreement." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1684693/000117891325001497/zk2533067.htm)) |
| August 20, 2026 | [Patidegib topical gel primary completion](https://sec-api.dev/pdufa/patidegib-topical-gel) | SLGL | Gorlin Syndrome | completed | "NCT06050122 (Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-20 (ACTUAL); Lead Sponsor Sol-Gel Technologies, Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06050122)) |
| Aug to Nov 2026 | [Patidegib topical gel topline data readout](https://sec-api.dev/pdufa/patidegib-topical-gel) | SLGL | Gorlin Syndrome | scheduled | "NCT06050122 (Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-20 (ACTUAL); Lead Sponsor Sol-Gel Technologies, Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06050122)) |
| Nov 2026 | [Patidegib topline data readout](https://sec-api.dev/pdufa/patidegib) | SLGL | Gorlin syndrome | scheduled | "With last patient last visit expected in September 2026 and top-line results anticipated in late November 2026, we are approaching the culmination of several years of work aimed at establishing topical patidegib as the first treatment designed to prevent the development of new basal cell carcinomas in patients with Gorlin syndrome." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1684693/000117891326004205/exhibit_99-1.htm)) |
| Nov 2026 | [Sol-Gel Technologies Ltd. topline data readout](https://sec-api.dev/companies/slgl/catalysts) | SLGL |  | scheduled | "Top-line results are expected in late November 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1684693/000117891326005177/exhibit_99-1.htm)) |

## Drugs

- [Epsolay (epsolay)](https://sec-api.dev/pdufa/epsolay): 
- [Patidegib](https://sec-api.dev/pdufa/patidegib): gorlin syndrome, severe, high-frequency basal cell carcinoma
- [Patidegib topical gel](https://sec-api.dev/pdufa/patidegib-topical-gel): Gorlin Syndrome

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/slgl/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SLGL catalysts: Sol-Gel Technologies Ltd. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/slgl/catalysts

```bibtex
@misc{secapidev_companies_slgl_catalysts_20261116,
  title        = {SLGL catalysts: Sol-Gel Technologies Ltd. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/slgl/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_slgl_catalysts_20261116","title":"SLGL catalysts: Sol-Gel Technologies Ltd. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/slgl/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
